Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression
Open accessPublished version of a preprint
The DOI matches its Crossref record, with a small difference in title or year; 113 of the 113 references it cites were found in a registry or an index; 22 of the 40 sources its claims cite were checked for support.
Abstract
This systematic review and meta-analysis evaluated the clinical effectiveness of various telemedicine interventions compared with usual care in glycemic control, and cardiovascular health in adults with T2DM. A random-effects model was used, analyzing 58 RCTs (13,942 participants) published up to August 2024. The pooled results showed a significant reduction in HbA1c levels in the telemedicine group compared with the control group (MD -0.38, 95% CI -0.49 to -0.27; P < .001). Subgroup analyses by duration revealed significant reductions in short-term and long-term, but not mid-term. Telemedicine delivered by physicians and dietitians showed significantly greater reduction in HbA1c.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 58 RCTs (13,942 adults with type 2 diabetes) found that telemedicine interventions improved HbA1c and several cardiometabolic outcomes compared with usual care. Effects were significant for HbA1c, fasting blood glucose, weight, BMI, and blood pressure, but not for HDL-c or LDL-c.
Key findings
- Telemedicine significantly reduced HbA1c versus usual care: MD –0.38, 95% CI –0.49 to –0.27; Z=6.94; P<.001, with high heterogeneity (I²=96%).
- Significant secondary improvements were found for fasting blood glucose (MD –11.29, 95% CI –17.65 to –4.93; P<.001), weight (MD –1.33, 95% CI –2.23 to –0.44; P=.004), BMI (MD –0.43, 95% CI –0.72 to –0.13; P=.004), systolic blood pressure (MD –2.14, 95% CI –3.02 to –1.26; P<.001), and diastolic blood pressure (MD –1.24, 95% CI –2.02 to –0.46; P=.002).
- No significant between-group differences were found for HDL-c (MD –3.41, 95% CI –2.67 to 9.49; P=.27) or LDL-c (MD –0.69, 95% CI –11.69 to 10.31; P=.90).
- Subgroup analyses showed significant HbA1c reductions across telemedicine types; interventions delivered by physicians, dietitians, and researchers achieved significant reductions, while those by nurses, pharmacists, medical teams, and coaches did not. Short-term and long-term interventions showed significant HbA1c improvements, but medium-term interventions did not. Meta-regression found no statistically significant moderators.
Methods
- Systematic review and meta-analysis following PRISMA, registered in PROSPERO (CRD42024608130); searched Embase, PubMed, Scopus, CINAHL, and Web of Science from inception to August 2024 for RCTs comparing telemedicine with usual care in adults with T2DM.
- Included 58 RCTs with 13,942 participants; primary outcome was HbA1c change, with secondary outcomes including mean glucose, fasting blood glucose, BMI, weight, systolic and diastolic blood pressure, HDL-c, and LDL-c.
- Random-effects meta-analysis was used; 47 studies contributed to the HbA1c meta-analysis, and 4 studies using 2 telemedicine types yielded 62 intervention groups. Subgroup analyses, meta-regression, Cochrane risk-of-bias assessment, GRADE, publication-bias assessment, and sensitivity analysis were performed.
Limitations
- The paper states high heterogeneity (I²=96%) likely due to variation in telemedicine content, media, providers, and duration; blinding was not possible; subgroup analyses had limited studies and high heterogeneity; and exclusion of non-English studies may be a source of publication bias.
- The paper also notes that publication-bias assessment showed borderline Egger significance (t=–1.98; P=.054), and trim-and-fill suggested 14 potentially missing studies, with an adjusted effect size of –0.607 (95% CI –0.800 to –0.414) versus the observed –0.379 (95% CI –0.579 to –0.180), so findings should be interpreted cautiously.
- Evident from the text: meta-regression did not identify any statistically significant moderators (provider approached significance at P=.084), and risk-of-bias concerns included high risk for blinding of participants/personnel in 30/58 studies (51%), unclear allocation concealment in 37/58 (64%), and high risk from other sources in 20/58 (34%).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Forest plot of the overall meta-analysis of the change in HbA1c between the telemedicine intervention group and the control group (47 studies [28,36-81]). *A study used 2 different telemedicine tools for the intervention, which are used here to differentiate. HbA1c: glycated hemoglobin.](https://figures.cochat.ai/paper-figures/fb8d8c81c50c425ba4f3d4223066d364/clinical-improvements-from-telemedicine-interventions-for-managing-type-2-figure-3.jpg)
![Figure 4 Forest plot of the subgroup meta-analysis of the change in HbA1c by type of telemedicine intervention (46 studies [28,36-42,44-81]). *A study used 2 different telemedicine tools for the intervention, which are used here to differentiate. HbA1c: glycated hemoglobin.](https://figures.cochat.ai/paper-figures/390b6bd2ec104eeb9a3227c07ebc7c71/clinical-improvements-from-telemedicine-interventions-for-managing-type-2-figure-4.jpg)
![Figure 5 Forest plot of the subgroup meta-analysis of the change in HbA1c by telemedicine provider (47 studies [28,36-81]). *A study used 2 different telemedicine tools for the intervention, which are used here to differentiate. HbA1c: glycated hemoglobin.](https://figures.cochat.ai/paper-figures/522e565a49e643e8863e26574c1ad726/clinical-improvements-from-telemedicine-interventions-for-managing-type-2-figure-5.jpg)
![Figure 6 Forest plot of the subgroup meta-analysis of the change in HbA1c by duration of telemedicine intervention (47 studies [28,36-81]). *A study used 2 different telemedicine tools for the intervention, which are used here to differentiate. HbA1c: glycated hemoglobin.](https://figures.cochat.ai/paper-figures/01ab9bf4bfae4100bdd486ab6a55fd41/clinical-improvements-from-telemedicine-interventions-for-managing-type-2-figure-6.jpg)

Verification
Claims the paper makes
12 Valid · 3 Not valid · 9 Not checked · 70 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The included studies exhibited substantial heterogeneity (I²=94%), a common finding in telemedicine reviews, where heterogeneity typically ranges from 65% to 99% [17,22,86,93].”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Discussion > Principal Findings
What the sources say
- Not checked — no full text of the sourcecites [17] source
- Not checked — no full text of the sourcecites [22] source
- Partly supportedcites [86] sourceExperimental — accuracy not yet measured
The Discussion reports substantial heterogeneity among the source paper’s included studies, but gives I² = 93.05%, not 94%. The Results likewise report high I² values of 87.8% and 93% for different models. (LLM, conf=0.88)
- Disputedcites [93] sourceExperimental — accuracy not yet measured
The Effect on HbA1C section reports substantial heterogeneity, but not I²=94%: it gives I²=69% for the primary 4–12-month analysis, 75% at ≤3 months, and 58% at >12 months. Table 4 also identifies 69% as the heterogeneity in the primary analysis. Page numbers were not available in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In diabetes management specifically, telemedicine interventions have shown promise in enhancing glycemic control outcomes [14,17].”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Introduction
What the sources say
- Supportedcites [14] source
The Discussion (Primary Outcome HbA1c; page not provided) reports more effective HbA1c improvements with telemedicine than with usual care. The Discussion conclusions also describe telemedical applications as promising for diabetes therapy, while noting that larger, longer studies are needed. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [17] source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The included studies exhibited substantial heterogeneity (I²=94%), a common finding in telemedicine reviews, where heterogeneity typically ranges from 65% to 99% [17,22,86,93].”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Discussion > Principal Findings
What the sources say
- Supportedcites [17] sourceExperimental — accuracy not yet measured
The cited Tchero et al. (2019) paper has no available full-text snippets in two paper-scoped searches, so its individual heterogeneity estimates could not be checked. A Semantic Scholar match (score 0.737) in “Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care” states the 65%–99% range and cites four reviews, including the attributed paper. This supports the attribution through a secondary citation, though it does not establish which endpoint comes from Tchero et al. (LLM, conf=0.72)
- Supportedcites [22] sourceExperimental — accuracy not yet measured
Alfarwan et al. (2024) reports substantial heterogeneity in its telemedicine meta-analysis, including I² values of 71.32% and 96.60%. It therefore supports the citing sentence’s general point that heterogeneity can be high. The paper-scoped snippets do not establish 65%–99% as a typical range across reviews; the citing sentence attributes that broader range to four references collectively. The prior weak-match verdict is not evidence that the paper argues against the claim. (LLM, conf=0.78)
- Partly supportedcites [86] sourceExperimental — accuracy not yet measured
The Discussion says large heterogeneity is often seen in telemedicine reviews and reports I² values of 58%–75% in one review and 99% in another. It supports the general point and the upper end, but not the claimed typical lower bound of 65%. (LLM, conf=0.88)
- Partly supportedcites [93] sourceExperimental — accuracy not yet measured
The Effect on HbA1C section reports large heterogeneity in this telemedicine review (I² = 75%, 69%, and 58%). It supports the general point that heterogeneity can be substantial, but not the claim that telemedicine reviews typically range from 65% to 99%; this review reports a value below that range and does not establish a typical range across reviews. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Existing reviews often focus on specific types of telemedicine tools [19-21], settings [22], or providers [23], which limit generalizability across broader diabetes care contexts.”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Introduction
What the sources say
- Not checked — no full text of the sourcecites [19] source
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
This paper is a review focused on synchronous teleconsultation for type 2 diabetes, so it exemplifies a review limited to a particular telemedicine approach. Its Discussion > Strengths and limitations says its conclusions may not generalize to all areas, but attributes that limitation to the trials’ geographic concentration and heterogeneity, not to reviews’ focus on particular tools, settings, or providers. Our copy does not establish that broader explanation for existing reviews. (LLM, conf=0.82)
- Supportedcites [21] source
The Methods > Eligibility Criteria section (page unavailable) identifies this as a review of diabetes-specific mHealth apps, a specific type of telemedicine tool. It therefore supports the part of the citing sentence to which this source is attached: an example of a review focused on a specific tool type. The broader generalizability statement is the citing authors’ framing, not a finding attributed specifically to this review. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [22] source
- Not checked — no full text of the sourcecites [23] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interventions delivered by physicians and dietitians had a greater impact on HbA1c than those delivered by other providers, suggesting that provider expertise may affect outcomes.”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Discussion > Principal Findings
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
51 more claims
Create a free account to see all 94 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 22
- The quote only partly states this claim. 1
Statistics that don’t add up
Each reported p-value recomputed from its test statistic and degrees of freedom.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Z=1.10; P=.002”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Abstract > Results
Reported p = .002 · recomputed p = .271
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Doesn’t add upz = 1.1reported p = .002 · recomputed p = .271The two fall on opposite sides of .05
“Z=1.10, p = .002”
- Consistentz = 6.94reported p < .001 · recomputed p < .001
“Z=6.94, p < .001”
- Consistentz = 3.48reported p < .001 · recomputed p < .001
“Z=3.48, p < .001”
- Consistentz = 2.91reported p = .004 · recomputed p = .004
“Z=2.91, p = .004”
- Consistentz = 2.84reported p = .004 · recomputed p = .005
“Z=2.84, p = .004”
3 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Results > Basic Characteristics of the Included Studies
“Additional studies were conducted in Africa (1/58, 2%), South America (1/58, 2%), and Oceania (2/58, 3%; Figure S1 in Section 5 in Multimedia Appendix 2).”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Results > Basic Characteristics of the Included Studies
“| | Africa | 2 (3) | 2 (3) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Abstract > Results
“Z=1.10”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Abstract > Results
“P=.002”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Discussion > Principal Findings
“The included studies exhibited substantial heterogeneity (I²=94%)”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Results > Sensitivity Analysis
“In the primary meta-analysis of HbA1c outcomes, significant heterogeneity (I²=96%) was observed.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Results > Effects of Telemedicine on the Clinical Indicators of Patients With T2DM
“Overall, all trials demonstrated a positive impact of telemedicine on glycemic control (including changes in HbA1c, mean glucose, and FBG), weight management (change in weight and BMI), and cardiovascular health monitoring (including changes in SBP, DBP, LDL-c, and HDL-c).”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Results > Effects of Telemedicine on the Clinical Indicators of Patients With T2DM
“| ×k | — | — | — | 1 | — | 1 | — | 1 | — |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The analysis showed more significant changes in HDL-c levels in the control group (MD –3.41, 95% CI –2.67 to 9.49; Z=1.10; P=.27).”
§ Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression > Results > Meta-Analysis of the Effects of Telemedicine in Secondary Outcomes
Reported -3.41 · recomputed 3.41
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“[91,92].”
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123 · cited 1×
“Currently, it affects more than 537 million adults, a number projected to increase to 783.2 million by 2045 [2].”
InfluentialEstimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“Evidence suggests that a 1% decrease in HbA 1c is associated with a 37% reduction in microvascular complications, a 21% reduction in diabetes-related mortality, and a 14% decrease in the risk of myocardial infarction [100].”
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“Diabetes is a chronic metabolic disorder with increasing prevalence worldwide, placing a significant burden on global health care systems [1].”
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697 · cited 2×
“Type 2 diabetes mellitus (T2DM) accounts for 90% of all diabetes cases [3].”
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Cardiovascular disease remains the leading cause of death among patients with T2DM [101].”
Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19)
Smith, A. C., Thomas, E., Snoswell, C. L., Haydon, H., Mehrotra, A., Clemensen, J., & Caffery, L. J. (2020) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x20916567 · Cited by 1,828 · cited 2×
“While the exact timing of natural disasters or infectious disease pandemics may be unpredictable, disruptions to medical services are certain to recur in the future [108].”
Dorsey, E. R., & Topol, E. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601705 · Cited by 1,211 · cited 3×
“Legal and policy reforms that ensure equitable reimbursement can enhance the accessibility and benefits of telemedicine for vulnerable groups [94,95].”
Research works printed but not linked: 2
- Jantraporn, R, 2019, J Med Assoc Thailand, 102, 523
- Mechanic, OJ, 2024, Treasure Island (Fl) Ineligible Companies. Disclosure: Yudy Persaud Declares No Relevant Financial Relationships with Ineligible Companies
Cited by
Crowley, M. J., Lewinski, A. A., Yang, Q., Hatch, D., Palipana, A., Bosworth, H. B., Kaufman, B. G., Chatterjee, R., Pennington, G., Matters, D., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00132 · Cited by 5
McGill, J. B., Donihi, A. C., Aktürk, H. K., Freeby, M., Gupta, A., Horton, W. B., Jadoon, M. N., Lathief, S., Miracle-López, S., Tan, C., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.011 · Cited by 3
Jiao, F., Ho, K. M., Chiang, L., Ko, S. H., & Chen, C. X. (2026) · Journal of Medical Internet Research · doi:10.2196/74046
“It has been effectively used to manage a range of conditions, including diabetes mellitus [7], cancer [8], acute pediatric conditions [9], orthopedic conditions, psychological diseases, cardiovascular diseases, and chronic pain [10].”
Tapia, C. B. M., Paz, M. M. C., Duchi, F. C. A., & Niama, A. N. C. (2026) · Esprint Investigación · doi:10.61347/ei.v5i1.267
Metadata
- Authors
- Jiang, S., Gao, X., Diao, H., Zhang, Y., Lu, G., Liu, X., & Li, Y.
- Affiliations
- Yangzhou University (CN)
- Northern Jiangsu People's Hospital (CN)
- Corresponding author
- Li, Yuping
- Venue
- JMIR mHealth and uHealth
- Publisher
- JMIR Publications Inc.
- Published
- 2026-02-18
- Volume
- 14
- Pages
- e70429
- ISSN
- 2291-5222 (ISSN-L)
- PMC
- PMC12961393
- OpenAlex
- W4414003606
- Cited by
- 6
- References
- 92
- Citations by year
- 2026: 6
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- JMIR mhealth and uhealth (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Telemedicine and Telehealth Implementation
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, telemedicine, glycemic control, HbA1c, fasting blood glucose, cardiovascular risk factors, blood pressure, serum lipids, weight loss, usual care comparison, telehealth intervention, diabetes management, health care access, health information technology, remote patient monitoring, teleconsultation, telecoaching, telepharmacy
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Telemedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.